PG-102

1. PG-102 decreases fat mass in humans (-9.87%).

   “In the Q2W group, body weight decreased by 3.68% with −9.87% fat mass reduction while lean mass change remained <1%.”

   Human trial60 mg Q2W14 weeks

   Efficacy and Safety of Extended-Interval PG-102, a GLP-1/GLP-2 Bispecific Agonist, in Adults with Type 2 Diabetes

   ADA Scientific Sessions 2026 abstract·5 Jun 2026

More on Fat mass

1. PG-102 decreases fasting plasma glucose in humans (-34.4 mg/dL vs -11.3 mg/dL placebo).

   “Mean FPG reductions were −34.4 mg/dL and −29.9 mg/dL with Q2W and Q4W dosing versus −11.3 mg/dL and −7.5 mg/dL with placebo.”

   Human trial60 mg Q2W14 weeks

   Efficacy and Safety of Extended-Interval PG-102, a GLP-1/GLP-2 Bispecific Agonist, in Adults with Type 2 Diabetes

   ADA Scientific Sessions 2026 abstract·5 Jun 2026

More on Fasting plasma glucose

1. PG-102 decreases HbA1c in humans (-1.41% (95% CI -1.94, -0.87; p<0.0001)).

   “PG-102 significantly reduced HbA1c versus placebo with placebo-adjusted least-squares mean differences of −1.41% (95% CI −1.94, −0.87; p<0.0001) for Q2W”

   Human trialversus placebo60 mg Q2W14 weeks

   Efficacy and Safety of Extended-Interval PG-102, a GLP-1/GLP-2 Bispecific Agonist, in Adults with Type 2 Diabetes

   ADA Scientific Sessions 2026 abstract·5 Jun 2026

More on HbA1c